ERBB2 and melanoma: In the last few years, more and more targeted therapy agents have been introduced for the management of several cancer diseases, such as trastuzumab in human epidermal growth factor receptor 2 (HER2 positive) breast cancer or gastric cancer [9,10], imatinib in in KIT+ gastrointestinal stromal tumor (GIST) [11], and B-rapidly accelerated fibrosarcoma (BRAF)-directed therapy with vemurafenib or dabrafenib/trametinib in melanoma [12].